Zobrazeno 1 - 10
of 2 117
pro vyhledávání: '"Shan, Jing"'
In this paper, we analyze the top-quark decay $t\to Wb$ up to next-to-next-to-next-to-leading order (N$^{3}$LO) QCD corrections. For the purpose, we first adopt the principle of maximum conformality (PMC) to deal with the initial pQCD series. Then we
Externí odkaz:
http://arxiv.org/abs/2404.11133
In this paper, we present an improved analysis of the top-quark pair production via the process $e^{+}e^{-}\to \gamma^{*}\to t\bar{t}$ near the threshold region up to next-to-next-to-next-to-leading order (N$^3$LO) QCD corrections. Near the threshold
Externí odkaz:
http://arxiv.org/abs/2312.15442
Autor:
Diaozhu Lin, Huisheng Xiao, Kexu Yang, Juan Li, Suiwen Ye, Yanqiong Liu, Shan Jing, Yang Lin, Yuanxun Yang, Lei Huang, Jing Yuan, Ziyan Li, Jinlan Yang, Huanhuan Gao, Ying Xie, Mingtong Xu, Li Yan
Publikováno v:
BMC Medicine, Vol 22, Iss 1, Pp 1-12 (2024)
Abstract Background TG103, a glucagon-like peptide-1 analog, is being investigated as an option for weight management. We aimed to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of TG103 injection in participants who are o
Externí odkaz:
https://doaj.org/article/1d44c4d557a049f3ae9cb6970b7f9349
Autor:
Ni, Panxianzhi, Duan, Dengbinpei, Xiong, Shuting, Zhong, Meng, Huang, Can, Shan, Jing, Yuan, Tun, Liang, Jie, Fan, Yujiang, Zhang, Xingdong
Publikováno v:
In Chemical Engineering Journal 1 October 2024 497
Publikováno v:
In Chinese Journal of Chemical Engineering October 2024 74:22-30
Publikováno v:
In Journal of Energy Chemistry October 2024 97:379-387
Publikováno v:
In Ophthalmology Science September-October 2024 4(5)
Publikováno v:
In Journal of Chromatography A 16 August 2024 1730
Autor:
Si, Xinxin, Zhang, Quan, Ning, Bo, Qiang, Lei, Li, Qiang, Liu, Yihao, Fan, Minjie, Shan, Jing, Shen, Guanlu, Lin, Zichen, Zheng, Pengfei
Publikováno v:
In Chemical Engineering Journal 1 August 2024 493
Autor:
Shan Jing, Yang Lin, Randy Dockens, David Marchisin, Bing He, Ihab G. Girgis, Anjaneya Chimalakonda, Bindu Murthy, Urvi Aras
Publikováno v:
Dermatology and Therapy, Vol 13, Iss 12, Pp 3153-3164 (2023)
Abstract Introduction Deucravacitinib, an oral, selective, allosteric tyrosine kinase 2 inhibitor, blocks cytokine signaling involved in psoriasis pathogenesis. This ethnic-bridging study evaluated deucravacitinib pharmacokinetics, tolerability, and
Externí odkaz:
https://doaj.org/article/138681b5e9fe48568e696414c32c2790